Business
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary endpoint expected mid-year 2023 HOUSTON, March
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Enrollment continuing to progress toward an interim analysis, planned when 30-50% of subjects reach the primary endpoint expected mid-year 2023\nHOUSTON, March 9, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.\n\n \n \n \n \n \n \n\n \nThe Company has opened 40 clinical trial sites of the 59 sites selected across the U.S., Italy, France, Spain, and Switzerland. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have reached the primary endpoint. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.\n\"The active patient enrollment we continue to build across our clinical trial sites in Europe is incredibly encouraging. Our team is laser focused on getting additional clinical trial sites online so that we can continue to advance toward our planned interim analysis, which we expect mid-year 2023. We are continually grateful to the institutions, clinicians and staff that are contributing to the conduct of this trial and are extremely grateful to the patients that choose to participate. There remains a significant unmet need in the treatment of GBM and we remain committed to advancing Berubicin to potentially offer a much-needed therapy for this devastating cancer,\" commented John Climaco, CEO of CNS Pharmaceuticals.\nProfessor Michael Weller, MD, University Hospital Zurich and National Coordinating Investigator for the potentially pivotal study, added, \"I believe Berubicin has the potential to play an important role in the treatment of this devastating disease. We are committed to working alongside the CNS Pharmaceuticals team to advance the development of Berubicin and are pleased to commence patient enrollment at our site(s) in Switzerland.\"\nBerubicin, is a novel anthracycline and the first anthracycline...